leon-nanodrugs GmbH (LEON) is a technology provider specializing in equipment for the manufacturing of nanoparticle-based drug products, including RNA-based lipid nanoparticles (LNPs).

LEON’s technology platform, featuring the modular FR-JET ® mixing reactor, enables a seamless transition from R&D to commercial-scale manufacturing, eliminating common challenges associated with tech transfer between scales.

LEON’s portfolio of devices, NANOlab® for process development, NANOme® and NANOus® for GMP aseptic manufacturing, enable faster route to clinical batches and are suitable for both individualised scales and commercial production.

For individualized mRNA therapies, NANOme® is a groundbreaking piece of equipment designed to meet stringent regulatory requirements. Featuring fully GMP-compliant, closed, and automated aseptic processing with single-use sterile fluid paths, NANOme® ensures rapid, back-to-back manufacturing and contamination-free production of patient-specific batches. LEON’s technology platform empowers drug developers to optimize their manufacturing processes effortlessly, ensuring rapid progression from development to commercial manufacturing.